Showing results (181-190 of 283) with videos related to

Sort By:
Pageof 29
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 9, 2003
A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancerH J Mackay, M O'Brien, S Hill, et al.
Lancet (London, England)|May 8, 1982
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour GroupN Thatcher, P V Barber, R D Hunter, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant diseaseN Thatcher, H Sharma, R Harrison, et al.
Cancer|January 1, 1988
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. From the Manchester Lung Tumour GroupN Thatcher, D B Smith, M J Lind, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Viridans streptococcal bacteraemia in patients with haematological and solid malignanciesA D Burden, B A Oppenheim, D Crowther, et al.
Cancer Treatment Reports|April 1, 1985
Activity of JM9 in advanced ovarian cancer: a phase I-II trialV H Bramwell, D Crowther, S O'Malley, et al.
British Journal of Cancer|February 1, 1996
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancerD C Betticher, J Heighway, P S Hasleton, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosisA G Kamthan, M J Lind, N Thatcher, et al.
European Journal of Nuclear Medicine|January 1, 1987
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanomaT Cerny, S E Owens, S A Mackenzie, et al.
British Journal of Cancer|April 1, 1990
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II studyN Thatcher, H Dazzi, M Mellor, et al.
Pageof 29